Astrana Health, Inc. ASTH
36.37
1.93
5.60%
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 43.6×
Follow ASTH
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
55.92 | 39.55 | 53.93 | 149.21 |
+8 more quarters Free account |
P/S ratio |
0.59 | 0.34 | 0.38 | 0.48 | |
P/FCF ratio |
24.15 | 7.73 | 11.65 | 14.39 | |
P/Operating CF |
69.61 | 17.60 | (421.89) | 140.16 | |
P/B ratio |
2.71 | 1.47 | 1.53 | 1.77 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.73 | 0.50 | 0.57 | 0.68 | |
EV/EBITDA |
16.75 | 12.02 | 14.24 | 19.49 | |
EV/Operating CF |
26.10 | 10.52 | 15.94 | 18.60 | |
EV/FCF |
29.83 | 11.27 | 17.48 | 20.44 | |
Quick Ratio |
1.19 | 1.31 | 1.35 | 1.36 | |
Current Ratio |
1.23 | 1.35 | 1.40 | 1.40 | |
Net Debt/EBITDA |
10.50 | 12.17 | 16.95 | 16.31 | |
Debt/Assets |
41.04% | 43.57% | 46.82% | 46.93% | |
Debt/Equity |
1.11 | 1.26 | 1.31 | 1.33 | |
Asset Turnover |
2.06 | 1.91 | 1.78 | 1.64 | |
Operating CF/Net income |
1.66 | 4.71 | (0.48) | 26.69 | |
Capex/Depreciation |
(0.23) | (0.24) | (0.17) | (0.15) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
5.57% | 6.40% | 6.34% | 6.53% | |
Intangible Assets out of Total Assets |
0.50 | 0.48 | 0.51 | 0.51 | |
Share Based Compensation of Revenue |
1.21% | 1.03% | 1.20% | 0.81% | |
Graham Net Nets |
(0.23) | (0.45) | (0.46) | (0.40) | |
Graham Number |
17.88 | 15.26 | 12.93 | 8.28 | |
Earnings Yield |
1.79% | 2.53% | 1.85% | 0.67% | |
Free Cash Flow Yield |
4.14% | 12.94% | 8.58% | 6.95% | |
Revenue per Share |
19.80 | 19.75 | 19.37 | 19.43 | |
Operating CF per Share |
0.67 | 1.39 | (0.06) | 0.20 | |
Capex per Share |
(0.08) | (0.08) | (0.06) | (0.05) | |
Free Cash Flow per Share |
0.59 | 1.31 | (0.12) | 0.15 | |
Cash per Share |
8.16 | 9.79 | 8.75 | 9.42 | |
Shareholders Equity per Share |
17.12 | 16.69 | 16.16 | 16.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.12 | 16.69 | 16.16 | 16.03 | |
Free Cash Flow |
28.87 | 64.06 | (5.95) | 7.40 | |
Working Capital |
171.52 | 258.73 | 248.04 | 253.70 | |
Capital Expenditures |
(3.88) | (4.00) | (3.06) | (2.55) | |
Net Current Asset Value |
(522.08) | (539.53) | (562.05) | (564.48) | |
EV/EBIT |
28.03 | 20.21 | 23.26 | 32.57 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
2.03% | 1.50% | 0.63% | 0.04% | |
Price to Operating Income |
22.69 | 13.85 | 15.51 | 22.93 | |
| Other line items | |||||
Average Receivables |
427.24 | 412.03 | 363.73 | 308.62 | |
Average Payables |
182.76 | 163.47 | 151.03 | 152.28 | |
Average Assets |
1,862.22 | 1,845.04 | 1,786.78 | 1,761.28 | |
Average Common Equity |
806.18 | 782.82 | 755.01 | 749.35 |
Columns are period end dates